Cogent Biosciences (COGT) Stock Price, News & Analysis

Company Overview

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Key Stats

• Today's Range: $7.27 to $7.73
• 50-Day Range: $4.64 to $7.62
• 52-Week Range: $3.72 to $12.61
• Volume: 1.86 million shs
• Average Volume: 1.35 million shs
• Market Capitalization: $867.04 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.43
• Consensus Rating: Moderate Buy

Cogent Biosciences Stock Analysis - MarketRank™

Cogent Biosciences scored higher than 56% of companies evaluated by MarketBeat, and ranked 1384th out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Cogent Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Cogent Biosciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cogent Biosciences are expected to grow in the coming year, from ($2.42) to ($2.20) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cogent Biosciences is -4.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cogent Biosciences is -4.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cogent Biosciences has a P/B Ratio of 5.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

15.65% of the float of Cogent Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Cogent Biosciences has a short interest ratio ("days to cover") of 9.9.

Change versus previous month

Short interest in Cogent Biosciences has recently increased by 15.44%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cogent Biosciences does not currently pay a dividend.

Dividend Growth

Cogent Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

15.65% of the float of Cogent Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Cogent Biosciences has a short interest ratio ("days to cover") of 9.9.

Change versus previous month

Short interest in Cogent Biosciences has recently increased by 15.44%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.88

News Sentiment

Cogent Biosciences has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for Cogent Biosciences this week, compared to 4 articles on an average week.

Search Interest

4 people have searched for COGT on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cogent Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 7.29% of the stock of Cogent Biosciences is held by insiders.

COGT Stock Analysis - Frequently Asked Questions

How have COGT shares performed this year?

Cogent Biosciences' stock was trading at $7.80 at the beginning of 2025. Since then, COGT stock has decreased by 2.4% and is now trading at $7.6150.

How were Cogent Biosciences' earnings last quarter?

Cogent Biosciences, Inc. (NASDAQ:COGT) issued its earnings results on Tuesday, May, 6th. The technology company reported ($0.52) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.04.

How do I buy shares of Cogent Biosciences?

Shares of COGT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cogent Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cogent Biosciences investors own include Visa (V), Tesla (TSLA), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX), NVIDIA (NVDA) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 5/06/2025
• Today: 7/04/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:COGT
• CIK: 1622229
• Web: www.cogint.com
• Phone: (617) 945-5576
• Fax: N/A
• Employees: 80
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $14.43
• High Stock Price Target: $25.00
• Low Stock Price Target: $7.00
• Potential Upside/Downside: +89.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.84)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$255.86 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -149.79%
• Return on Assets: -75.61%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.13
• Quick Ratio: 5.13

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.32 per share
• Price / Book: 5.77

Miscellaneous

• Outstanding Shares: 113,860,000
• Free Float: 105,556,000
• Market Cap: $867.04 million
• Optionable: Optionable
• Beta: 1.88